The greenlight for Journavx (suzetrigine), which comes on the heels of a $7.4 billion opioid settlement, could spark momentum ...
The FDA has accepted for review the NDA for bumetanide nasal spray for edema associated with CHF, as well as hepatic and renal disease.
Domestic formulation sales increased by 13.8 per cent to Rs 4,300.4 crore Y-o-Y, representing 32 per cent of the company's ...
HonorHealth announced the creation of its new international Center for Translational Science. Sanofi said it will repurchase $5.2 billion of stock and grow profits faster this year as the drugmaker ...
Sequentially, revenue from operations grew by 2.9 per cent, whereas profit after tax (PAT) fell by 4.5 per cent ...
The Food and Drug Administration’s approval of low-risk tobacco pouches is welcome, but why did it delay for more than four ...
The drug represents a new pathway to treating people with pain due to surgeries or traumatic injuries, avoiding the addictive ...
The FDA just approved a new type of pain medication, and it's a non-opioid called suzetrigine that stops body pain at its ...
The medication offers relatively modest pain relief, underscoring the challenges of finding new ways to manage pain.
A new pain relief drug, suzetrigine, is a prescription pill that’s taken every 12 hours after a larger starter dose. It will ...
The Food and Drug Administration Jan. 30 announced it approved Journavx (suzetrigine) oral tablets, a first-in-class ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback